Drug profile · INN
toripalimab-tpzi
LOQTORZI
toripalimab-tpzi (LOQTORZI) is a programmed cell death protein 1 antagonist. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
Drug details — toripalimab-tpzi
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 3
- Programs
- 20
- Data quality
- 0.89
Quick answer
toripalimab-tpzi (LOQTORZI) is a programmed cell death protein 1 antagonist. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is toripalimab-tpzi?
toripalimab-tpzi (LOQTORZI) is a programmed cell death protein 1 antagonist. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for toripalimab-tpzi?
LOQTORZI is a marketed brand name for toripalimab-tpzi. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of toripalimab-tpzi?
toripalimab-tpzi has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.